Plné znění - 80/2017 Sb. m. s.

Sdělení o přijetí nového znění Přílohy I (Seznam zakázaných látek a metod dopingu pro rok 2017 - Mezinárodní standard) Mezinárodní úmluvy proti dopingu ve sportu

80/2017 Sb. m. s.

Sdělení

INFORMACE

80

XXXXXXX

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,

xxxxxx xx xxxx x xxxxxxxx xxxxxxx Ministerstva xxxxxxxxxxxx xxxx x. 58/2007 Sb. m. x. x x. 46/2008 Xx. x. x.

 

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, že xxx 28. listopadu 2016 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX xxxxxxxx xxxxxxxxx xxxxxx znění Přílohy X (Seznam zakázaných xxxxx x xxxxx xxxxxxx pro rok 2017 - Xxxxxxxxxxx xxxxxxxx) Xxxxxxxxxxx úmluvy xxxxx xxxxxxx xx xxxxxx¹⁾.

X xxxxx xxxxxx Xxxxxxx I xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx xxxxxxxxx a prezident xxxxxxxxx podepsal listinu x přijetí xxxx Xxxxxxx X Xxxxxx xxxxxxxxxx.

Xxxx znění Xxxxxxx X xxxxxxxxx x xxxxxxxx x souladu x článkem 34 xxxx. 3 Úmluvy xxx 1. ledna 2017 x pro Českou xxxxxxxxx vstoupilo x xxxxxxxx xxx 30. xxxxx 2017.

Dnem vstupu xxxxxx xxxxx Xxxxxxx X x xxxxxxxx xxxxxxxx platit xxxxx Xxxxxxx X platné xx 1. xxxxx 2016, vyhlášené xxx č. 26/2017 Sb. m. s.

Xxxxxxxx xxxxx Xxxxxxx X x xxxx xxxxxxx xx českého xxxxxx xx vyhlašují xxxxxxxx.

XXXXXXX XXXXXXXXXXXXX XXXXX

XXXXXX XXXXXXXXXX LÁTEK X XXXXX XXXXXXX XXX XXX 2017

MEZINÁRODNÍ XXXXXXXX

Xxxxxxxxx xxxx Xxxxxxx bude xxxxxxxxx WADA a xxxx xxxxxxxxxx x xxxxxxxxxx x xxxxxxxxxxxxx.

X xxxxxxx jakýchkoliv xxxxxxxxx xxxx anglickou x xxxxxxxxxxxx xxxxx xxxx xxxxxxxxxxx xxxxxxxx xxxxx.

Xxxxx Xxxxxx bude xxxxxx xx 1. ledna 2017 

XXXXXX XXXXXXXXXX XXXXX X XXXXX DOPINGU XXX XXX 2017

XXXXXXX XXXXXXXXXXXXX XXXXX

Xxxxxx xx 1. xxxxx 2017

Xxxxx xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxx xxxxxxx Xxxxxxxx xxxxx budou xxxxxxxxxx za "Xxxxxxxxxx xxxxx" xxxxx xxxxx xx skupin S1, X2, S4.4, X4.5 x X6(x) a Xxxxxxxxxx xxxxx M1, X2 a X3.

XXXXX X XXXXXX XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)

XXXXXXXX XXXXX

X0. XXXXXXXXXXX XXXXX

Xxxxxxxxx xxxxxxxxxxxxxx xxxxxx xxxxx, která xxxx xxxxxxxx v xxxxxxxxxxxxx sekcích Xxxxxxx x xxxx aktuálně xxxxxxxxx xxx xxxxxxx xxxxxxxxxxxx použití xxxxxxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. xxxxxx x xxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx výzkumu xxxx xx xxxxxxxx xxxxxxxxxx, xxxxxxxxxx xxxxx, xxxxx xxxxxxxxx xxxxx xxx veterinární xxxxxxx), xx xxxxxxxx xxxxx.

X1. XXXXXXXXXX XXXXX

Xxxxxxxxxx xxxxx xxxx zakázány.

1. XXXXXXXXXX XXXXXXXXXX STEROIDY (AAS):

(a) Xxxxxxxx* AAS, xxxxxxxxxx:

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3ß,17ß-xxxx);

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx);

xxxxxxxxx (xxxx-4-xx-3ß, 17ß-xxxx);

xxxxxxxxxx;

xxxxxxx ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17α-ol);

dehydrochlormethyltestosteron (4-xxxxxx-17ß-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);

xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17ß-xx);

xxxxxxxxxxx;

xxxxxxxxxxxxx (19-xxxxxxxxx-4-xx-17α-xx);

xxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx (17α-xxxxxx[1,2,5]xxxxxxxxxx[3',4':2,3]-5α-xxxxxxxxx-17ß-xx);

xxxxxxxxx;

4-xxxxxxxxxxxxxxxxxx (4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx);

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx (17ß-hydroxy-17α-methylandrosta-1,4-dien-3-on);

metenolon;

methandriol;

metasteron (17ß-hydroxy-2α,17α-dimethyl-5α-androstan-3-on);

methyldienolon (17ß-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx);

xxxxxx-1-xxxxxxxxxxx (17ß-hydroxy-17α-methyl-5α-androst-1-en-3-on);

methylnortestosteron (17ß-hydroxy-17α-methylestr-4-en-3-on);

methyItestosteron;

metribolon (xxxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx (17ß-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxxx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

1-xxxxxxxxxxx (17ß-xxxxxxx-5α-xxxxxxx-1-xx-3-xx);

xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18α-xxxx-19-xxx-17α-xxxxxx-4,9,11-xxxxx-3-xx);

xxxxxxxxx (17ß-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx biologickými xxxxxx.

x. Xxxxxxxxx** XXX, xxxxx jsou podány xxxxxxxx:

Xxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx);

xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx);

xxxxxxxx;

xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx);

xxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-5α-xxxxxxxxx-3xx); 

xxxxxxxxx (19-xxxxxxxxxxxxxx);

19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx);

19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx);

xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX, 3ß-xxxxxxxxxxxxxx-5-xx-17-xx);

xxxxxxxxxxx;

x xxxxxx xxxxxxxxxx x isomery, xxx xx x xxxxxxxx xxxxx na xx:

5α-xxxxxxxxx-3α,17α-xxxx;

5α-xxxxxxxxx-3α,17ß-xxxx;

5α-xxxxxxxxx-3ß,17α-xxxx;

5α-xxxxxxxxx-3ß,17ß-xxxx;

5ß-xxxxxxxxx-3α,17ß-xxxx;

5α-xxxxxxx-2-xx-17-xx;

xxxxxxx-4-xx-3α,17α-xxxx;

xxxxxxx-4-xx-3α,17ß-xxxx;

xxxxxxx-4-xx-3ß,17α-xxxx;

xxxxxxx-5-xx-3α,17α-xxxx;

xxxxxxx-5-xx-3α,17ß-xxxx;

xxxxxxx-5-xx-3ß,17α-xxxx;

4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3ß,17ß-xxxx);

5-xxxxxxxxxxxxx (androst-5-en-3,17-dion);

androsteron;

epi-dihydrotestosteron;

epitestosteron;

etiocholanolon;

3ß-hydroxy-5α-androstan-17-on;

7α-hydroxy-DHEA;

7ß-hydroxy-DHEA;

7-keto-DHEA;

19-norandrosteron;

19-noretiocholanolon.

2. Xxxxxxx xxxxxxxxxx xxxxx, xxxxxxxxxx:

Xxxxxxxxxxx; selektivní modulátory xxxxxxxxxxxxx receptorů (XXXX, xxxx. xxxxxxx a xxxxxxx); xxxxxxx; xxxxxxx x zilpaterol, ale xx x omezením xxxxx na xx.

Xxx xxxxx skupiny této xxxxx: * "exogenní" xx xxxxxxxx k xxxxx, xxxxxx tělo xxxxxxxx xxxxxxxxx xxxxxxxxxxx. ** "xxxxxxxxx " se xxxxxxxx x xxxxx, kterou xxxx xxxxxxxx xxxxxxxxx xxxxxxxxx.

X2. PEPTIDOVÉ XXXXXXX, XXXXXXX XXXXXXX, XXXXXXXX XXXXX A MIMETIKA

Následující xxxxx x další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky xxxx xxxxxxxx:

1. Xxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxx:

1.1 Xxxxx xxxxxxxxxxx xxxxxxxxxxx (XXX) xxxxxx xxxx.

xxxxxxxxxxxx (xXXX);

xxxxxxxxxxxxx (XXX);

XXX-Xx;

XXX-xxxxxxxxxxx xxxxxxx (EMP), xxxx. CNTO 530 x peginesatid;

inhibitory GATA, xxxx. X-11706;

xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx beta (XXXX);

xxxxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxxx xxxxxxx xxxx (TGF-beta), xxxx. xxxxxxxxxxx, luspatercept;

1.2 Xxxxxxxx xxxxxxxxxxxxxxxxxx XXX xxxxxxxxx, xxxx.

XXX-290;

xxxxxx XXX;

xxxxxxxxxxxxx XXX;

2. Stabilizátory hypoxii xxxxxxxxxxxxxx xxxxxxx (XXX), xxxx. xxxxxx, xxxxxxxxxx x roxadustat (FG-4592); x xxxxxxxxxx XXX, xxxx. xxxxx x xxxxx.

3. Xxxxxxxxxxxxxxxxxx (CG) x xxxxxxxxxxxx xxxxxx (XX) a xxxxxx xxxxxxxxxx xxxxxxx, xxxx. xxxxxxxxx, gonadorelin x xxxxxxxxxxx, x xxxx.

4. Xxxxxxxxxxxxxx a xxxxxx xxxxxxxxxx xxxxxxx, xxxx. xxxxxxxxxxxx.

5. Růstový hormon (XX) x jeho xxxxxxxxxx xxxxxxx xxxxxx: xxxxxxx xxxxxxxxxxxx xxxxxxx xxxxxx (GHRH) x xxxx xxxxxxx, např. XXX-1295, sermorelinu a xxxxxxxxxxxx; xxxxxxxxxxx xxxxxxxxx xxxxxxx (GHS), xxxx. xxxxxxxx a xxxxxxx xxxxxxxx, např. xxxxxxxxxxx x ipamorelinu; xxxxxxxxxxxx xxxxxxx xxxxxxxxx hormonu (XXXX), xxxx. xxxxxxxxxxxxx, XXXX-6, hexarelinu x xxxxxxxxxxxx (XXXX- 2).

Xxxxx xxxx xxxx xxxxxxxx xxxxxxxxxxx xxxxxxx faktory:

Fibroblastové xxxxxxx xxxxxxx (XXXx); xxxxxxxxxxxx xxxxxxx xxxxxx (XXX); insulinu xxxxxxx xxxxxxx xxxxxx-1 (XXX-1) x xxxx xxxxxxx; xxxxxxxxxx růstové faktory (XXX); růstový faktor xxxxxxxx z xxxxxxxx xxxxxxxx (XXXX); xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx faktor (XXXX), xxxxxx jako jakékoliv xxxx růstové xxxxxxx xxxxxxxxxxx xxxxxxx xxxx xxxxxxxxx xxxxxxxx xxxxx, xxxxx x vaziva, xxxxxx zásobení, využití xxxxxxx, regenerativní xxxxxxxx xxxx ovlivňující xxxx xxxxxxxxx vláken.

S3. XXXX2- XXXXXXXX

Xxxxxxx xxxxxxxxxx x xxxxxxxxxxxx xxxx2- xxxxxxxx, xxxxxx xxxxx xxxxxxxxx xxxxxxx, xxxx xxxxxxxx.

Xxxxxxxx (xxx ne x xxxxxxxx pouze xx xx):

Xxxxxxxxx; xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx.

Xxxxxxxx xxxx:

• xxxxxxxxx xxxxxxxxxx: maximálně 1600 xxxxxxxxxx xx 24 xxxxx, xxxxxxxxxxx 800 xxxxxxxxxx xx xxxxxxx 12 hodin;
• inhalační formoterol: xxxxxxxxx xxxxxx dávka 54 xxxxxxxxxx za 24 xxxxx;
• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 200 xxxxxxxxxx xx 24 hodin.

Přítomnost xxxxxxxxxxx x xxxx x xxxxxxxxxxx vyšší xxx 1000 xx/xx x xxxxxxxxxx xxxxxxxxxxx x xxxx x xxxxxxxxxxx xxxxx xxx 40 xx/xx xxxxxx xxxxxxxxxx xx zamýšlené xxxxxxxxxxxx xxxxxxx, ale xxxx považována xx xxxxxxxxx xxxxxxxxxxx nález, xxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx farmakokinetickou studií, xx abnormální výsledek xxx xxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxx (x xxxxxxxx) nižší, xxx xxxx xxxxxxx xxxxxxxxx xxxxx.

X4. XXXXXXXXX A XXXXXXXXXXX XXXXXXXXXX

Xxxxxxxx jsou xxxxxxxxxxx xxxxxxxxx x xxxxxxxxxxx xxxxxxxxxx:

1. Inhibitory xxxxxxxx, zahrnující:

Aminoglutethimid;

anastrozol;

androsta-1,4,6-trien-3-17-dion (xxxxxxxxxxxxxxxxx);

xxxxxxxx-3,5-xxxx-7-17-xxxx (xxxxxxxxx);

4-xxxxxxxxx-3,6,17-xxxxx (6-xxx);

xxxxxxxxx;

xxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx,

xxx xx x omezením pouze xx xx.

2. Xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx receptorů (XXXX), xxxxxxxxxx:

Xxxxxxxxx;

xxxxxxxxx;

xxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.

3. Xxxxxxx xxxxxxxxxxxxxx xxxxx xxxxxxxxxx:

Xxxxxxxxxx; fulvestrant x xxxxxxxx, xxx xx x xxxxxxxx xxxxx xx ně.

4. Xxxxx modifikující xxxxxx(x) xxxxxxxxxx xxxxxx inhibitorů xxxxxxxxxx, xxx xx

x xxxxxxxx xxxxx na xx.

5. Xxxxxxxxxxx modulátory:

5.1 Xxxxxxxxxx AMP-aktivované xxxxxxxxxxxxx (XXXX), např. XXXXX; x Xxxxxxxx Receptoru xxxxx aktivovaného xxxxxxxxxxxxxx xxxxxxxxxxxxx (XXXXδ), xxxx. XX 1516;

5.2 Xxxxxxxx x xxxxxxxx insulinů;

5.3 Xxxxxxxxx;

5.4 Xxxxxxxxxxxx.

X5. XXXXXXXXX X XXXXXXXXX XXXXX

Xxxxxxxxxxx xxxxxxxxx a maskovací xxxxx xxxx zakázané, xxxxxx xxxx xxxxx xxxxx x xxxxxxxx xxxxxxxxx strukturou a xxxxxxxxx xxxxxxxxxxxx xxxxxx.

Xxxxxxxx:

• Xxxxxxxxxxxx, xxxxxxxxxxxxxxx (např. glycerol, xxxxxxxxxx xxxxxx xxxxxxxx, xxxxxxxx, xxxxxxxxxxxxxxxxxx x xxxxxxxxx), xxxxxxxxxx, ale xx x xxxxxxxx xxxxx na ně.

• Acetazolamid, xxxxxxxx, bumetanid, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxx xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxx (např. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), xxxxxxxxxx x xxxxxxx (xxxx. xxxxxxxxx), xxx xx x omezením xxxxx xx xx.

X xxxxxxxx:

• xxxxxxxxxxxx, pamabromu x xxxxxx xxxxxx inhibitorů xxxxxxxxxxxxxx (xxxx. dorzolamidu x xxxxxxxxxxxx)

• Xxxxxxxxx xxxxxx xxxxxxxxxxxx xxx xxxxx xxxxxxxxx

Xxxxx xxxxxxxxxxx množství xxxxx xx xxxxxxxxxx xxxxxxxx xxxxxxx (xx. xxxxxxxxxx, salbutamol, katin, xxxxxxx, xxxxxxxxxxxx a xxxxxxxxxxxxx) ve Xxxxxx Xxxxxxxxx xxxxxxxx xxxx

xxxxxxxx Xxx Soutěži xx xxxxxxx s diuretikem xxxx xxxxx xxxxxxxxx xxxxxx, xxxx xxxxxxxxxx xx Xxxxxxxxx laboratorní xxxxx, xxxxx Xxxxxxxxx xxxx schválenou Xxxxxxxxxxxxx xxxxxxx (XX) xx xxxx látku xxxxx x xx, xxxxx xxx xxxx xxxxxxx xx xxxxxxxxxx nebo xxxxx xxxxxxxxx xxxxx.

XXXXXXXX XXXXXX

X1. MANIPULACE X XXXX X KREVNÍMI XXXXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Xxxxxx nebo znovuzavedení xxxxxxxxxxx množství xxxxxxxxx, xxxxxxxx (homologní) xxxx xxxxxxxxxxx xxxx nebo xxxxxxxxx xxxxxxx a xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx systému.

2. Xxxxx xxxxxxxxx xxxxxxxx, xxxxxxx xxxx dodávky kyslíku.

Zahrnující:

modifikované xxxxxxxxxxxxx produkty (xxxx. xxxxxx xxxxxxxx xxxxxxxx xx xxxxxxxxxxx x xxxxxxxxxxxxxxxxxx xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx x efaproxiral (XXX13), xxx xx s xxxxxxxx xxxxx xx xx. Inhalační xxxxxxxxxxxx xxxxxxxx xxxxxxxx xxxx.

3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx xxxx s xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxx způsoby.

M2. CHEMICKÁ X XXXXXXXXX XXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Xxxxxxxxx, xxxx Xxxxx x Xxxxxx, xx xxxxxx xxxxxxx xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx. Xx xxxxxxxx záměnu x/xxxx xxxxxx (xxxx. xxxxxxxxxx) xxxx, ale xx s xxxxxxxx xxxxx na ně.

2. Xxxxxxxxxx infuze x/xxxx xxxxxxx více xxx 50 xx xx 6 hodin xxxxx xxxxxx legitimně xxxxxxxxx x xxxxxxx nemocničních xxxxxxx, chirurgických xxxxxxx xxxx klinických xxxxxxxxxxxxx xxxxx.

X3. XXXXXX XXXXXX

X xxxxxx potenciálu xx xxxxxxx xxxxxxxxxxx výkonu xx xxxxxxxx následující:

1. Xxxxxxxx xxxxxxxx nukleových xxxxxxx xxxx jejich xxxxxxx;

2. Použití xxxxxxxxxx xxxx geneticky modifikovaných xxxxx;

XXXXX X XXXXXX XXXXXXXX XXX XXXXXXX

Xxxxx xxxxxxxxx S0 až X5 a X1 xx M3 uvedených xxxx

xxxx Xxx Xxxxxxx xxxxxxxx x xxxxxxxxxxx xxxxxxx:

XXXXXXXX XXXXX

X6. STIMULANCIA

Všechna xxxxxxxxxxx xxxxxx xxxxx xxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx, např. d- x I-, jsou xxxxxxxx.

Xxxxxxxxxxx xxxxxxxx:

(x) Nespecifická xxxxxxxxxxx:

Xxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxxx /4-fenylpiracetam (karfedon)/,

furfenorex,

klobenzorex,

kokain,

kropropamid,

krotetamid,

lisdexamfetamin,

mefenorex,

mefentermin,

metamfetamin (x-),

xxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxxxxx, 

x-xxxxxxxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxx.

Xxxxxxxxxxxx, xxxxx není xxxxxxxx uvedeno v xxxxx odstavci, je Xxxxxxxxxxx látkou.

(b) Specifická xxxxxxxxxxx.

Xxxxxxxx (xxx xx x xxxxxxxx xxxxx xx ně):

Adrenalin (xxxxxxxxx)****,

xxxxxxxxxxx,

xxxxxxxxxxxxxxxxx,

xxxxxxx***,

xxxxxxxx,

xxxxxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxxx x xxxx deriváty,

fenkamfamin,

fenmetrazin,

fenprometamin,

heptaminol,

hydroxyamfetamin (xxxxxxxxxxxxxxxxxxxx),

xxxxxxxxxxxx,

xxxxx**,

xxxxxxx x xxxx xxxxxxx (xxxx. mefedron, xxxxxxxxx x xxxx-xxxxxxxxxxxxxxxxxxxxx),

xxxxxxxxxxxxxxx,

xxxxxxxxxxxx,

xxxxxxxxxxxx***,

xxxxxxxxxxxxxxxxxxxxxxxx,

xxxxxxxxxxxx,

4-xxxxxxxxxx-2-xxxx (xxxxxxxxxxxxxx),

xxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxx (xxxxxxxxxxxxx),

xxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxxxxxx,

xxxxxxxxxxxxx*****,

xxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxxx (metylendioxyamfetamin),

tuaminoheptan

a xxxxx látky x xxxxxxxx chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

X xxxxxxxx:

• xxxxxxxxx

• xxxxxxxx xxxxxxxxx x případě jejich xxxxxxxx/xxxxxx xxxxxxx x xxxxxxxxxxx zahrnutých do Xxxxxxxxxxxxxx xxxxxxxx xxx xxx 2017*.

* Xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, pipradrol x xxxxxxxx: Xxxx xxxxx xxxx zahrnuté do Xxxxxxxxxxxxxx programu 2017 x xxxxxx považovány xx Xxxxxxxx xxxxx.

** Xxxxx: je xxxxxxxx xxxxx xxx xxxxxxxxxxx xxxxx xxx 5 xxxxxxxxxx x 1 xx moči.

*** Xxxxxxx x xxxxxxxxxxxxx: jsou xxxxxxxx xxx koncentraci xxxxx xxx 10 xxxxxxxxxx x 1 xx moči.

**** Xxxxxxxxx (xxxxxxxxx): xxxx zakázán xxx xxxxxxxx podání, xxxx. xxxxx, oční xxxxxxxx nebo xxxx xxxxxx xxxxxxxx x xxxxxxxxx xxxxxxxxxx.

***** Xxxxxxxxxxxxx: xx xxxxxxx, xxxxx xxxx xxxxxxxxxxx x xxxx xx xxxxx xxx 150 mikrogramů xx xxxxxxxx.

X7. XXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

Xxxxxxxxxxx,

xxxxxxxxxxxxx,

xxxxxxxxx(xxxxxx),

xxxxxxxx x xxxx xxxxxxxx,

xxxxxxxxxxx,

xxxxxxx,

xxxxxx,

xxxxxxxxxx,

xxxxxxxx,

xxxxxxxxx,

xxxxxxxxxx,

xxxxxxx.

X8. KANABINOIDY

Zakázané xx xxxxxxxxxxx:

• Xxxxxxxx (xxxx. xxxxx, xxxxxx x xxxxxxxxx) xxxx xxxxxxxxxx xxxxx9-xxxxxxxxxxxxxxxxxxx (XXX).

• Xxxxxxxxxxxxxx, xxxx. "Xxxxx", JWH018, XXX073 x XX-210.

X9. XXXXXXXXXXXXXXX

Xxxxxxx xxxxxxxxxxxxxxx podávané xxxxxx, xxxxxxxx, xxxxxxxxxx nebo xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxx.

XXXXX ZAKÁZANÉ V URČITÝCH XXXXXXXX

X1. ALKOHOL

Alkohol (xxxxxx) xx zakázaný pouze Xxx Soutěži x xxxxxxxxxxxxx xxxxxxxx. Xxxxxxx xx xxxx xxxxxxxx xxxxxxxx zkouškou a/nebo xxxxxxxx xxxx. Prahová xxxxxxx xxx xxxxxxxx xxxxxxxxxxx pravidla je xxxxxxxxxxxx xxxxxxxxxxx xxxxxxxx x xxxx 0,10 x/x.

• Xxxxxxxxxxxx xxxxx (FIA)

• Lukostřelba (XX)

• Xxxxxxx sporty a xxxxxxxxxxxx (FAI)

• Vodní xxxxxxxxxx (XXX)

X2. XXXX-XXXXXXXXX

Xxxx-xxxxxxxxx xxxx xxxxxxxx pouze x xxxxxxxxxxxxx xxxxxxxx Při Xxxxxxx, x kde xx xx označeno x Xxxx xxxxxx.

• Xxxxxxxxxxxx xxxxx (XXX)

• Xxxxxxxx (xxxxxxx xxxxxxxxxx) (WCBS)

• Golf (XXX)

• Xxxxxxxxxxx (XX)*

• Xxxxxxxx (XXX) - xxxxx xx xxxxxx x xxxxxxxxxxx xxxxxxxx-xxxxx x X-xxxxx, x xxxxxxxxx U-rampa x "xxx air"

• Podvodní xxxxxx (xxxxxxxxx potápění) (CMAS) x xxxxxxxxxxxx xxxxxxxxxx xxxx s ploutvemi xxxx bez xxxxxxx, xxxxxxxxx xxxxx x xxxxxxxxx xxxx xxx xxxxxxx, xxxx xxxxxxxxx, xxxx blue, xxxxxxxxxxxx, xxxxxxxx apnoe, střelba xxxxxxxx xx xxxx x xxxxxxxxxx xxxx.

• Xxxxxxx (XXXX, XXX)*

• Xxxxx (WDF)

* Xxxxxxxx xxxx Xxxx xxxxxx

Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx:

Xxxxxxxxxx,

xxxxxxxxxx,

xxxxxxxx,

xxxxxxxxx,

xxxxxxxxxx,

xxxxxxx,

xxxxxxxxxx,

xxxxxxx,

xxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxxxx,

xxxxxxxxxx, 

xxxxxxx,

xxxxxxxxxx,

xxxxxxxx,

xxxxxxxxxxx,

xxxxxxx,

xxxxxxx,

xxx xx x xxxxxxxx xxxxx na xx.

Informace

Právní xxxxxxx č. 80/2017 Xx. m. x. xxxxx xxxxxxxxx xxxx 4.1.2018.

Xxxxxx xxxxxxx x. 80/2017 Xx. x. x. xxx xxxxxx právním xxxxxxxxx č. 36/2019 Sb. m. s. x xxxxxxxxx xx 26.7.2019.

Xxxxx jednotlivých xxxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxx v xxxxxxxx xxxx aktualizováno, xxxxx xx jich xxxxxx derogační xxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx.

1) Mezinárodní xxxxxx xxxxx xxxxxxx xx xxxxxx, xxxxxxx xxx 19. října 2005 x Xxxxxx, xxxx xxxxxxxxx x xxxxxxxxx xxxxx a x xxxxxxxxx do českého xxxxxx pod č. 58/2007 Sb. m. s.

Xxxx xxxxx xxxxxxxx Úmluvy xx českého jazyka xxxx xxxxxxxxx xxx č. 46/2008 Sb. m. s.